# AMSER Case of the Month: November 2018

# 42 year old with right breast mass



Rina Kiyota Petek Lake Erie College of Osteopathic Medicine, OMS-III Kossivi Dantey, MD Bibianna Klepchick, MD Matthew Hartman, MD Allegheny General Hospital





### **Patient Presentation**

- HPI: Patient is a 42 yo female that presented with a palpable right breast mass for 2 months. Patient last had mammography 2 years prior. Patient denies breast pain, tenderness, skin changes, or discharge from nipples.
- PMHx: LMP 3.5 mo ago, chlamydia, female infertility
- PSHx: No pertinent surgical hx
- Family Hx: DM, HTN, paternal aunt had breast cancer, maternal great aunt had breast cancer
- Medications: none



### Physical Exam

General Appearance: No apparent distress

Neck: Thyroid normal, no masses

Skin: No rashes, lesions, or ulcers

C/V: Normal heart sounds, no murmurs or external edema

Lungs: Respiratory effort normal. Lungs clear bilaterally

GI: No masses, tenderness, heme, hernias, or liver enlargement. Spleen not palpable

Abdomen: Benign, soft, non-tender, no hernia, masses, or lymphadenopathy

Breast Exam: Moderate fibrocystic condition of both breasts, A rounded lump noted in the left breast at 2 o'clock location approximately 8cm from the nipple, measures 3 cm in diameter and approximately 1 cm in depth. It is quite well circumscribed, movable, rubbery, nontender. No axillary lymphadenopathy. No galactorrhea.

# **MASER**



Extremely dense breast tissue. There is a spiculated mass in the posterior upper inner quadrant of the right breast with overlying BB marker indicating site of palpable abnormality. There are no suspicious calcifications.



### Ultrasound



Right PALP 1:00 7CM FN

Focused sonography of the right breast over palpable abnormality demonstrates an irregular hypoechoic mass with posterior shadowing without increased internal vascularity.

BIRADS 5- Highly suggestive of malignancy



# Differential diagnosis based on imaging

- Malignancy
- Fibrocystic change
- Fibroadenoma
- Intraductal papilloma
- Foreign body reaction/granuloma
- Idiopathic Granulomatous Lobular Mastitis
- Sclerosing adenosis
- Radial scar



### Ultrasound-guided needle biopsy

1.0



Invasive ductal carcinoma nuclear grade 2 E-Cadherin (+) Smooth muscle myosin heavy chain/p63 (-)

BIRADS 6- Known biopsyproven malignancy

Right PALP 1:00 7CM FN Biopsy



### Needle Localization

Adv Breast AHN eL18-4 68Hz RS



TIS0.1 MI 0.6

Yellow arrows: needle advancedthrough mass



#### Right 1:00 7 CM FN NDLOC

# Gross pathology from lumpectomy and confirmation







Pathology- H&E Low Mag



Malignant ductal cells invading surrounding stroma and invading into normal fatty tissue of the breast



# Pathology- H&E High Mag



Cellular pleomorphism with large cells and large nucleoli. Mitotic figures present



# Pathology

- Invasive ductal carcinoma, nuclear grade 3: Estrogen receptor (+), Progesterone receptor (+), HER2/Neu (-)
- Ductal carcinoma in situ, nuclear grade 2, solid, micropapillary and cribriform types, with comedonecrosis and calcifications
- Margins free of invasive and in situ carcinoma; lymphovascular invasion not identified
- Pathologic stage: pT2 N0(sn) MX



### Final Dx:

### Invasive Ductal Carcinoma with Ductal Carcinoma in Situ



### Invasive Ductal Carcinoma: Discussion

- Ductal carcinoma in situ accounts for almost 1/5<sup>th</sup> of all breast cancers detected by screening in North America
- Risk factors: older age, benign breast disease, family history of breast cancer, nulliparity, older age of first pregnancy
- Due to screening mammograms, almost 90% of ductal carcinomas in situ are diagnosed while clinically occult due to detection of microcalcifications, soft-tissue densities, or both, which trigger investigation via stereotactic core needle biopsy.



### Invasive Ductal Carcinoma: Discussion

- Pathobiologic events associated with ductal carcinoma in situ and invasive ductal carcinoma
  - Abnormal response to growth factors-i.e. estrogen receptor, progesterone receptor
  - Loss of tumor-suppressor function- i.e. p53
  - Abnormal oncogene expression- i.e. HER2/neu
  - Genetic instability
  - Tissue invasion, stromal changes, clinical phenotype of tumor determined



# Radiographic features of malignant breast lesions

- Mammogram:
  - Greater density, spiculated or irregular mass, asymmetry from other breast tissue, pointed irregular calcifications that are heterogeneous in size or fine and branching calcifications
- Ultrasound:
  - Hypoechoic lesions with irregular or ill-defined borders, can be "taller than broader", posterior acoustic shadowing, and microcalcifications.



### Pathologic features of ductal carcinoma

Pathologic classification of ductal carcinoma in situ and ductal carcinoma:

•Nuclear grade of tumor cells- low, intermediate, high

•Architectural pattern of tumor growth- solid, papillary, micropapillary, or cribriform

•Presence or absence of comedonecrosis

High grade lesions and lesions associated with comedonecrosis are associated with greatest risk of recurrence after breast conserving procedures.

Immunohistochemistry:

•Hormone status: Estrogen receptor, Progesterone receptor

• Used to predict potential treatment response to tamoxifen

•Oncogenes: HER-2/Neu

• Used as a marker for sensitivity for trastuzumab and resistance to tamoxifen

	Ductal Carcinoma/DCIS	Lobular Carcinoma	Benign lesion
Myoepithelial markers: smooth muscle actinin, calponin, p63, SMMHC	(-)	(-)	(+)
E-Cadherin	(+)	(-)	(+/-)
CK8	(-)	(+)	(+/-)

### **References:**

Kim YR, Kim HS, Kim H-W. Are Irregular Hypoechoic Breast Masses on Ultrasound Always Malignancies?: A Pictorial Essay. Korean Journal of Radiology. 2015;16(6):1266-1275. doi:10.3348/kjr.2015.16.6.1266.

Franquet, T., C. D. Miguel, R. Cozcolluela, and L. Donoso. Spiculated lesions of the breast: mammographic-pathologic correlation. RadioGraphics 13:841–852, 1993.

Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situof the breast. N Engl J Med. 2004 Apr 1;350(14):1430-41. Review. PubMed PMID:15070793.

McKenna RJ Sr. The abnormal mammogram radiographic findings, diagnostic options, pathology, and stage of cancer diagnosis. Cancer. 1994 Jul 1;74(1Suppl):244-55. PubMed PMID: 8004594.

Gokhale S. Ultrasound characterization of breast masses. The Indian Journal of Radiology&Imaging. 2009;19(3):242-247. doi:10.4103/0971-3026.54878.

Zaha DC. Significance of immunohistochemistry in breast cancer. World Journal of Clinical Oncology. 2014;5(3):382-392. doi:10.5306/wjco.v5.i3.382.

